Reportedly, Maik Jornitz has been an active member of the PDA since 1994, holding a number of voluntary functions. He was also member of the task forces that drafted technical reports on sterile filtration and depth filtration, and headed the 2008 PDA annual meeting. He was elected in 2004 to the board of directors and has been chair-elect of the board since 2007.
In addition to Mr. Jornitz, the PDA board consisting of 17 members includes representatives from the pharmaceutical companies, Pfizer, Novartis, GlaxoSmithKline, Amgen, Baxter, Roche/Genentech, Abbott and Hoffmann-La-Roche. Maik Jornitz’s term as PDA chair will run until the end of 2011.
Maik Jornitz has been associated with the Sartorius Group for 23 years. The biotech manager is an internationally recognized expert in filtration technologies with a focus on sterile filtration, process validation and integrity testing for biopharmaceutical applications. He has authored and co-authored nine scientific books and seven chapters, and regularly publishes technical papers in scientific and trade journals.
The not-for-profit PDA organization has over 10,000 members worldwide, who predominantly work at companies, research institutes and government agencies that deal with the development, manufacture, quality control and approval of drugs and other pharmaceutical products.